Advertisement
Screener

Ovid Therapeutics Inc. (OVID) Graph

OVID Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $733.00K; Revenue including tax (m); Research and development $9.96M; Selling, general and administrative (m).
  • 2026-03-31: Revenue $0.00; Revenue including tax (m); Research and development $11.18M; Selling, general and administrative (m).
  • 2025-12-31: Revenue $718.00K*; Revenue including tax (m); Research and development $6.59M*; Selling, general and administrative (m).
  • 2025-09-30: Revenue $132.00K; Revenue including tax (m); Research and development $5.87M; Selling, general and administrative (m).

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

OVID revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$733.00KRevenue$733.00KOperating expenses$16.43MOperating income-$15.70MOther income, net$689.00KResearch & development$9.96MPre-tax income-$15.01MIncome tax$0.00Net income-$15.01M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$733.00K(m)$9.96M(m)$16.43M$0.00-$15.01M
2026-03-31$0.00(m)$11.18M(m)$17.85M$0.00-$16.99M
2025-12-31$718.00K*(m)$6.59M*(m)$13.01M*$0.00*$9.68M*
2025-09-30$132.00K(m)$5.87M(m)$12.65M$0.00-$12.16M
2025-06-30$6.27M(m)$6.46M(m)$11.35M$0.00-$4.68M
2025-03-31$130.00K(m)$6.66M(m)$12.68M$0.00-$10.23M
2024-09-30$173.00K(m)$7.86M(m)$13.40M$0.00-$14.01M
2024-06-30$169.00K(m)$12.58M(m)$20.69M$0.00$8.52M
2024-03-31$148.00K(m)$10.40M(m)$17.57M$0.00-$11.69M
2023-09-30$109.00K(m)$5.33M(m)$12.14M$0.00-$11.25M
2023-06-30$75.00K(m)$6.00M(m)$14.25M$0.00-$12.41M
2023-03-31$66.00K(m)$6.62M(m)$14.96M$0.00-$13.36M
2022-09-30$11.10K$11.10K$5.18M(m)$12.81M$0.00-$11.97M
2022-06-30$0.00$0.00$6.05M(m)$14.30M$0.00-$14.59M
2022-03-31$1.45M$1.45M$7.83M(m)$17.71M$50.00K-$16.11M
2021-09-30(m)$0.00$4.92M(m)$11.68M-$294.83K-$11.38M
2021-06-30(m)$0.00$7.68M(m)$14.31M$1.47M-$15.79M
2021-03-31(m)$208.38M$16.25M(m)$31.83M$500.28K$176.01M
2020-09-30(m)$6.91M$15.88M(m)$23.32M(m)-$16.42M
2020-06-30(m)(m)$16.03M(m)$23.14M(m)-$22.55M
2020-03-31(m)(m)$14.63M(m)$20.29M(m)-$20.03M
2019-12-31(m)(m)(m)(m)$17.27M(m)-$16.97M
2019-09-30(m)(m)$11.60M(m)$16.77M(m)-$16.63M
2019-06-30(m)(m)$9.12M(m)$13.32M(m)-$13.06M
2019-03-31(m)(m)$9.34M(m)$14.05M(m)-$13.80M
2018-12-31(m)(m)(m)(m)$13.12M(m)-$12.90M
2018-09-30(m)(m)$8.54M(m)$13.18M(m)-$12.96M
2018-06-30(m)(m)$8.12M(m)$13.21M(m)-$12.94M
2018-03-31(m)(m)$8.47M(m)$13.43M(m)-$13.18M
2017-12-31(m)(m)(m)(m)$11.05M(m)-$10.96M
2017-09-30(m)(m)$5.90M(m)$9.41M(m)-$9.36M
2017-06-30(m)(m)$6.07M(m)$10.29M(m)-$10.25M
2017-03-31(m)(m)$31.28M$2.98M$34.26M$0.00-$34.24M
2016-12-31(m)(m)(m)(m)$7.59M(m)-$7.56M
2016-09-30(m)(m)$2.70M(m)$5.82M(m)-$5.79M
2016-06-30(m)(m)$1.77M(m)$5.42M(m)-$5.39M
2016-03-31(m)(m)$1.13M$2.59M$3.71M$0.00-$3.68M

Revenue and expense 6 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2026-06-30$733.00K(m)$21.14M$34.27M$0.00-$32.00M
2025-06-30$6.40M(m)$13.12M$24.02M$0.00-$14.92M
2024-06-30$317.00K(m)$22.98M$38.25M$0.00-$3.17M
2023-06-30$141.00K(m)$12.61M$29.20M$0.00-$25.77M
2022-06-30$1.45M$1.45M$13.88M$32.02M$0.00-$30.70M
2021-06-30(m)$208.38M$23.93M$46.14M$1.97M$160.22M
2020-06-30(m)(m)$30.66M$43.44M(m)-$42.58M
2019-06-30(m)(m)$18.45M$27.38M(m)-$26.86M
2018-06-30(m)(m)$16.59M$26.64M(m)-$26.12M
2017-06-30(m)(m)$37.36M$44.55M(m)-$44.49M
2016-06-30(m)(m)$2.90M$9.13M(m)-$9.07M

Revenue and expense 9 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2025-09-30$6.53M(m)$18.99M$36.68M$0.00-$27.08M
2024-09-30$490.00K(m)$30.84M$51.65M$0.00-$17.18M
2023-09-30$250.00K(m)$17.95M$41.34M$0.00-$37.02M
2022-09-30$1.46M$1.46M$19.06M$44.83M$0.00-$42.66M
2021-09-30(m)$208.38M$28.85M$57.82M$1.68M$148.83M
2020-09-30(m)$6.91M$46.53M$66.75M(m)-$59.01M
2019-09-30(m)(m)$30.05M$44.14M(m)-$43.49M
2018-09-30(m)(m)$25.17M$39.81M(m)-$39.08M
2017-09-30(m)(m)$43.26M$53.96M(m)-$53.85M
2016-09-30(m)(m)$5.59M$14.95M(m)-$14.85M

Revenue and expense 12 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2025-12-31$7.25M(m)$25.58M$49.69M$0.00-$17.40M
2024-12-31$566.00K(m)$36.77M$62.45M$0.00-$26.40M
2023-12-31$392.00K(m)$28.59M$59.67M$0.00-$52.30M
2022-12-31$1.50M(m)$24.62M$57.05M$0.00-$54.17M
2021-12-31$208.38M$208.38M$46.94M$84.17M$1.33M$122.83M
2020-12-31(m)$12.62M$63.42M$94.05M$0.00-$81.04M
2019-12-31(m)(m)$42.16M$61.41M$0.00-$60.46M
2018-12-31(m)(m)$33.79M$52.93M$0.00-$51.98M
2017-12-31(m)(m)$49.97M$65.01M$0.00-$64.81M
2016-12-31(m)(m)$9.59M$22.54M(m)-$22.41M
2015-12-31(m)(m)$6.61M$13.19M(m)-$13.16M

Similar stocks

Stock NameCountryMarket CapPE Ratio
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53
ARVINAS, INC. (ARVN)United States$0.510B58.38
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Evolus, Inc. (EOLS)United States$0.519B-13.32
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63
Indaptus Therapeutics, Inc. (INDP)United States$0.537B